Abstract
Diabetic macular edema (DME) is one of causes leading to visual acuity loss in the diabetic population.In recent years,great progress has been achieved in the treatment for DME.While laser photocoagulation and pars plana vitrectomy remain the standard of care,a new wave of methods,including intravitreal corticosteroid and anti-vascular endothelial growth factor (anti-VEGF) medications,is emerging and shows the preliminary safety and efficacy profile for DME by a number of clinical trials.This article introduce the definition,classification,pathogenesis and the different treatment methods for DME,so to aid ophthalmologists in evaluating the most appropriate and up-todate management options in managing DME.Particular attention is paid to summarize recent peer-reviewed literatures of ranibizumab (Lucentis). Key words: Ranibizumab; Anti-angiogenesis; Corticosteroid; Diabetic macular edema; Diabetic retinopathy
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
